Personalised Cancer Vaccine Cuts Risk of Melanoma Recurrence or Death in Trial

A clinical trial has shown that a personalised cancer vaccine, used alongside immunotherapy, reduced the risk of melanoma returning or causing death by 42 per cent.

The finding concerns the combined treatment, rather than the vaccine used on its own. It points to a potential role for personalised vaccination alongside immunotherapy in treating melanoma.

The reported reduction covers a combined measure of recurrence or death. It does not mean that each outcome fell separately by 42 per cent, or that the treatment eliminated either risk.

The available summary does not specify the trial’s size, follow-up period or comparison treatment. Those details are needed to assess the result fully and understand its implications for patients.